Incidence and Risk Factors of Glaucoma Following Pediatric Cataract Surgery With Primary Implantation.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
04 2021
Historique:
received: 24 06 2020
revised: 10 09 2020
accepted: 10 09 2020
pubmed: 21 9 2020
medline: 15 5 2021
entrez: 20 9 2020
Statut: ppublish

Résumé

To determine the incidence and risk factors for glaucoma after pediatric cataract surgery with intraocular lens (IOL) implantation. Retrospective, consecutive case series. In this single-center study, we reviewed 136 children (199 eyes) who underwent pediatric cataract surgery before 1 year of age with a minimum of 1 year of follow-up. The intervention used was pediatric cataract surgery with IOL implantation, and the primary outcome measure was the presence or absence of secondary glaucoma. The mean age at surgery was 148 ± 93 days (range 30-359 days) with a mean follow-up of 6.3 ± 3.6 years (range 1.1-12.8 years). Glaucoma developed in 31 eyes (16%) with 5- and 10-year incidence rates of 12% and 28%, respectively. The incidence of glaucoma seemed to be bimodal, with a first peak occurring after a mean delay of 2.5 months (range 1.6-4.1 months) and a second peak occurring after a mean delay of 5.7 years (range 2.6-11.7 years). Younger age at surgery, shorter axial length, longer follow-up, use of trypan blue, reintervention, and bilateral surgery were associatied with a higher incidence of glaucoma. Multivariate analysis including the aforementioned variables indentified longer follow-up (odds ratio [OR] = 1.3 [95% confidence interval {CI} 1.1-1.6], P = .001), reintervention (OR = 4.1 [95% CI 1.2-13.4], P = 0.02), and the use of trypan blue (OR = 4.1 [95% CI 1.3-13.1], P = .02) as predictors for the development of glaucoma. Glaucoma is a common complication after pediatric cataract surgery. It seemed to have a bimodal incidence. Risk factors for glaucoma development were reintervention, the use of trypan blue, and a long follow-up.

Identifiants

pubmed: 32950509
pii: S0002-9394(20)30519-5
doi: 10.1016/j.ajo.2020.09.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Youssef Abdelmassih (Y)

Department of Pediatric Ophthalmology, Fondation Ophtalmologique Rothschild, Paris, France.

Pauline Beaujeux (P)

Department of Pediatric Ophthalmology, Fondation Ophtalmologique Rothschild, Paris, France.

Pascal Dureau (P)

Department of Pediatric Ophthalmology, Fondation Ophtalmologique Rothschild, Paris, France.

Catherine Edelson (C)

Department of Pediatric Ophthalmology, Fondation Ophtalmologique Rothschild, Paris, France.

Georges Caputo (G)

Department of Pediatric Ophthalmology, Fondation Ophtalmologique Rothschild, Paris, France. Electronic address: gcaputo@for.paris.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH